Boehringer’s Dual-Action Obesity Drug Survodutide Shows Strong Weight Loss and Metabolic Benefits
In a major development in the fight against obesity, Boehringer Ingelheim has announced encouraging results for its experimental drug survodutide, offering new hope for people struggling with overweight and obesity.










